Brought to you by 
AstraZeneca takes on Targacept's cognitive disorder candidate; deal ends
15 Aug 2016
Executive Summary
AstraZeneca has licensed exclusive worldwide development and commercialization rights to Targacept's (central nervous system therapeutics) TC1734 (ispronicline) to treat Alzheimer's disease, schizophrenia, and other cognitive disorders. Targacept retains the option to co-promote the compound and any others that arise from the collaboration.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AstraZeneca takes on Targacept's cognitive disorder candidate; deal ends
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice